Hillsdale Investment Management Inc. Purchases 41,500 Shares of Omnicell, Inc. $OMCL

Hillsdale Investment Management Inc. boosted its position in Omnicell, Inc. (NASDAQ:OMCL) by 40.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 144,427 shares of the company’s stock after acquiring an additional 41,500 shares during the period. Hillsdale Investment Management Inc. owned 0.32% of Omnicell worth $4,398,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of OMCL. Raymond James Financial Inc. purchased a new stake in shares of Omnicell during the second quarter worth about $26,000. First Horizon Corp bought a new position in Omnicell during the 3rd quarter valued at approximately $31,000. Farther Finance Advisors LLC lifted its holdings in Omnicell by 784.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after buying an additional 1,036 shares during the period. LSV Asset Management bought a new stake in shares of Omnicell in the 3rd quarter worth approximately $97,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Omnicell by 385.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock valued at $146,000 after buying an additional 3,932 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

OMCL has been the subject of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $49.00 price target (down previously from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Weiss Ratings raised shares of Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, February 9th. Benchmark lifted their target price on shares of Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Wall Street Zen downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Zacks Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $54.50.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president owned 91,674 shares in the company, valued at approximately $4,574,532.60. The trade was a 6.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.52% of the stock is currently owned by company insiders.

Omnicell Stock Up 4.2%

Shares of Omnicell stock opened at $40.26 on Monday. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.00. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of 1,006.75, a PEG ratio of 1.49 and a beta of 0.78. The company has a 50-day moving average of $45.50 and a 200 day moving average of $37.67. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.40 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business had revenue of $313.98 million for the quarter, compared to the consensus estimate of $313.36 million. During the same period in the previous year, the firm earned $0.60 EPS. The company’s revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. As a group, sell-side analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.